Kancera AB, a biotechnology company, engages in the development and sale of drug candidates that cure or stop the progression of cancer. Its pharmaceutical development projects include PFKFB3 project, which targets the ability of solid tumors, such as breast, prostate, lung, and colon cancer to survive and resist chemotherapy and radiotherapy treatment; and ROR-1 project that aims to develop a targeted drug to treat chronic lymphatic leukemia. The company was founded in 2010 and is based in Solna, Sweden.
(KAN:OMX Nordic Exchange Stockholm)
Karolinska Institutet Science Park
Solna, 171 48
Phone: 46 8 50 12 60 80
|No competitor information is available for KAN.|
|View Industry Companies|
|Price/Cash Flow||NM||Not Meaningful|
Sponsored Financial Commentaries
To contact KANCERA AB, please visit www.kancera.com. Company data is provided by Capital IQ. Please use this form to report any data issues.